MARKETSnap
  • Gainers &
    Losers
  • Most Active &
    More
  • 52-Week
    High/Low
  • P/E
    Ratios
    • Large Caps
    • Absolute
    • Total Market PE
  • Stocks
    Performance
    • Large Caps
    • Absolute
  • Industries
    Performance
    • Industry
    • Sector
  • Dividends
  • 📅 Calendar
    • Earnings Calendar
    • Dividends Calendar
    • Economics Calendar
  • 🔧 Tools
    • 💰 Intrinsic Value Calculator
    • 📈 Compounding Calculator
    • 🤖 Stock Pick Screener
  • More
    • Investment Compounding Calculator
    • Commodities
    • Currencies
    • Economic Indicators
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
ARGX stock logo

ARGX

argenx SE

$882.35
-1.65
 (-0.19%)
Exchange:  NASDAQ
Market Cap:  54.603B
Shares Outstanding:  15.705M
Delayed data
Calculate ARGX Intrinsic Value
5-year outlook →
Overview
Earnings
Financials
Valuation
Chart

About The Company

Sector:  Healthcare
Industry:  Biotechnology
   
CEO:  Timothy Van Hauwermeiren
Full Time Employees:  1599
Address: 
Laarderhoogtweg 25
Amsterdam
1101EB
NL
Website:  https://www.argenx.com
argenx SE, a biotechnology company established in Amsterdam, the Netherlands, in 2008, is dedicated to developing innovative therapies primarily for autoimmune diseases. The company’s operations span across key global markets, including the United States, Japan, Europe, the Middle East, Africa, and China. Its leading investigational therapy is efgartigimod, which is being developed to address a broad range of conditions. These include generalized myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary Sjögren’s syndrome, post-COVID postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, ANCA-associated vasculitis, and antibody-mediated rejection. Also noted in connection with its lead product efforts is ENHANZE SC. The company’s extensive development pipeline features several other promising candidates. Empasiprubart is in development for multifocal motor neuropathy, delayed graft function, and dermatomyositis. ARGX-119 is being investigated for congenital myasthenic syndrome and amyotrophic lateral sclerosis. Further pipeline assets include ARGX-213, which targets FcRn; ARGX-121 and ARGX-220, both designed to modulate the immune system; ARGX-109, which targets IL-6; and ARGX-118, developed for inflammatory indications. argenx is also advancing cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. The company’s portfolio encompasses several proprietary products and brands, such as VYVGART, VYVGART HYTRULO, VYVDURA, ARGENX, ABDEG, NHANCE, SIMPLE ANTIBODY, and ARGENXMEDHUB. Strategic collaborations are integral to argenx’s business model. It maintains partnerships with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S, alongside numerous collaboration and license agreements with entities including Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., and Shire International GmbH. A specific collaboration with Genmab A/S focuses on the discovery, development, and commercialization of novel therapeutic antibodies for immunology and oncology applications. Additionally, argenx has a strategic collaboration with IQVIA Holdings Inc. for the provision of safety systems and related services.

Click to read more…

Revenue Segmentation

MARKETSnap

Log in to continue

Log in to see the complete revenue and geographic breakdown.

Login — it's free

EPS

Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.

Log in to continue

Log in for the full EPS chart and links to analyst estimates.

Login — it's free
View full analyst estimates

Earnings Call

Full text

Earnings transcript

Read the complete earnings call transcript.

AI summary

Key takeaways

Short, structured highlights from the call so you can focus on what matters.

2025/05/08 — Q1 quarter 2025

Log in to continue

Log in to read the full transcript and AI-generated earnings summaries.

Login — it's free
Income Statement
Balance Sheet
Cash Flow Statement
Analyst Estimates

Income Statement

Year202320242025
Revenue1,226,3162,190,2314,153,482
Gross Profit1,108,4811,962,9423,702,817
EBITDA-192,285105,1711,310,791
Operating Income-425,049-21,6541,054,615
Net Income-295,053833,0401,292,035

Log in to continue

Log in to see the income statement and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Balance Sheet

Year202320242025
Total Assets4,542,4586,202,5228,682,698
Total Liabilities444,951704,2391,359,606
Total Stockholders Equity4,097,5075,498,2837,323,092
Total Debt20,00039,05383,487
Cash and Cash Equivalents2,048,8441,499,9363,491,289

Log in to continue

Log in to see the balance sheet and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Cash Flow Statement

Year202320242025
Operating Cash Flow-420,327-82,747850,485.457
Capital Expenditure-43,812-68,301-6,184.077
Free Cash Flow-464,139-151,048844,301.380
Net Income-425,049833,0401,296,032.818
Net Change in Cash1,248,104-548,9081,991,353

Log in to continue

Log in to see the cash flow statement and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Analyst Estimates

Fiscal Year2030Full AccessFull AccessFull AccessFull Access
Estimated Revenue (Low)10,479,507.528Full AccessFull AccessFull AccessFull Access
Estimated Revenue (High)12,341,393.829Full AccessFull AccessFull AccessFull Access
Estimated Revenue (Avg)11,103,997.929Full AccessFull AccessFull AccessFull Access
Estimated Ebitda (Low)-3,907,418.081Full AccessFull AccessFull AccessFull Access
Estimated Ebitda (High)-3,317,924.844Full AccessFull AccessFull AccessFull Access
Estimated Ebitda (Avg)-3,515,645.224Full AccessFull AccessFull AccessFull Access
Estimated Net Income (Low)3,645,040.468Full AccessFull AccessFull AccessFull Access
Estimated Net Income (High)4,502,260.790Full AccessFull AccessFull AccessFull Access
Estimated Net Income (Avg)3,932,558.742Full AccessFull AccessFull AccessFull Access
Estimated SGA Expense (Low)6,594,358.494Full AccessFull AccessFull AccessFull Access
Estimated SGA Expense (High)7,765,973.258Full AccessFull AccessFull AccessFull Access
Estimated SGA Expense (Avg)6,987,326.729Full AccessFull AccessFull AccessFull Access
Estimated EPS (Avg)59.560Full AccessFull AccessFull AccessFull Access
Estimated EPS (High)68.190Full AccessFull AccessFull AccessFull Access
Estimated EPS (Low)55.200Full AccessFull AccessFull AccessFull Access
Number of Analysts (Estimated Revenue)10Full AccessFull AccessFull AccessFull Access
Number of Analysts (Estimated EPS)5Full AccessFull AccessFull AccessFull Access

Log in to continue

Log in and subscribe to Full Access to see up to 5 years of analyst estimates.

Login — it's free

(* All numbers are in thousands)

Current Key Metrics

?Revenue
 (TTM)
: 
2.186B  ?P/S
 (TTM)
: 
16.17
?Net Income
 (TTM)
: 
831.568M  ?P/E
 (TTM)
: 
48.02
?Enterprise Value
 (TTM)
: 
51.21B  ?EV/FCF
 (TTM)
: 
68.94
?Dividend Yield
 (TTM)
: 
0  ?Payout Ratio
 (TTM)
: 
0
?ROE
 (TTM)
: 
0.17  ?ROIC
 (TTM)
: 
0.12
?Net Debt
 (TTM)
: 
-3339773000  ?Debt/Equity
 (TTM)
: 
0.01
?P/B
 (TTM)
: 
7.4  ?Current Ratio
 (TTM)
: 
5.23

Log in to continue

Log in to see all key valuation metrics and ratios for this symbol.

Login — it's free

Forward P/E Ratios

?

Forward P/E (Avg EPS estimate) — log in with Full Access for high/low estimates and the interactive table.

Forward P/E 1YFull AccessFull AccessFull AccessFull Access
25.14Full AccessFull AccessFull AccessFull Access

Log in to continue

Log in with Full Access for forward P/E high/low estimates and the full multi-year table.

Login — it's free

SWOT Analysis

🔒 You are currently logged out

Login

It's free

At what price to buy it? -
Intrinsic Value Calculator

This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.

[intrinsic_calculator]

Common questions about ARGX valuation

Is argenx SE (ARGX) overvalued or undervalued right now?

MARKETSnap estimates intrinsic value for argenx SE (ARGX) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.

Is ARGX a buy, hold, or sell for long-term investors?

MARKETSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether ARGX trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.

What is ARGX’s P/E ratio?

You can see ARGX’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.

How is intrinsic value calculated for ARGX?

MARKETSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MARKETSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.

Is ARGX a good long-term investment?

Whether ARGX fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MARKETSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.

ARGX

1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.

Daily snapshot

-0.19
MARKETSnap

Trading Metrics:

Open: 881.11   Previous Close: 884
Day Low: 874.84   Day High: 888.5
Year Low: 510.06   Year High: 934.62
Price Avg 50: 799.53   Price Avg 200: 803.63
Volume: 124733   Average Volume: 325320

Log in to continue

Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.

Login — it's free
See in Nexus

Relevant news

ARGX Shares Gain Nearly 9% in a Month: Here's What You Need to Know
10-06-2026 09:11
ARGX Shares Gain Nearly 9% in a Month: Here's What You Need to Know
Argenx (ARGX) Soars 5.8%: Is Further Upside Left in the Stock?
08-06-2026 10:01
Argenx (ARGX) Soars 5.8%: Is Further Upside Left in the Stock?
argenx Touts VYVGART Growth, 50,000-Patient Goal at William Blair Conference
05-06-2026 06:03
argenx Touts VYVGART Growth, 50,000-Patient Goal at William Blair Conference
argenx Announces U.S. FDA Approval Expanding VYVGART and VYVGART Hytrulo for Use in All Adult Patients Living with gMG
08-05-2026 17:20
argenx Announces U.S. FDA Approval Expanding VYVGART and VYVGART Hytrulo for Use in All Adult Patients Living with gMG
argenx SE (ARGX) Q1 2026 Earnings Call Transcript
07-05-2026 17:11
argenx SE (ARGX) Q1 2026 Earnings Call Transcript
argenx to Report First Quarter 2026 Financial Results and Business Update on May 7, 2026
30-04-2026 01:00
argenx to Report First Quarter 2026 Financial Results and Business Update on May 7, 2026

DISCLAIMER: The stock market data provided on this website is for informational purposes only and is not intended for trading purposes. While we strive to provide accurate and timely information, we cannot guarantee that the information is accurate at the moment it is received or that it will continue to be accurate in the future. We are not responsible for any actions taken based on the information provided on this website. Always consult with a licensed financial professional before making any investment decisions.
Terms of Service

Copyright © 2025 MarketSnap. All rights reserved.

Contact Us

Privacy Policy

Cookie Policy

Terms of Service

Hover Image
MARKETSnap

Market

🇺🇸 United States

Language

  • Gainers & Losers
  • Most Active & More
  • 52-Week High/Low
  • Dividends
    • Large Caps
    • Absolute
    • Total Market PE
    • Large Caps
    • Absolute
    • Industry
    • Sector
    • Earnings Calendar
    • Dividends Calendar
    • Economics Calendar
  • 💰 Stock intrinsic value Calculator
  • 📈 Investment Compounding Calculator
  • 🤖 Stock Pick Screener
  • 📋 Watchlist & Portfolio
    • Commodities
    • Currencies
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
  • Nexus
  • Login Login
  • Profile Profile
  • Watchlists Watchlists
  • My Valuations My Valuations
  • Settings Settings

Media

Watch Listen Read